

ElÅ¼bieta Senkus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/887849/publications.pdf>

Version: 2024-02-01

77
papers

9,999
citations

126907

33
h-index

85541

71
g-index

81
all docs

81
docs citations

81
times ranked

11846
citing authors

#	ARTICLE	IF	CITATIONS
1	Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation. <i>New England Journal of Medicine</i> , 2017, 377, 523-533.	27.0	2,256
2	Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1194-1220.	1.2	1,241
3	4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). <i>Annals of Oncology</i> , 2018, 29, 1634-1657.	1.2	891
4	3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). <i>Annals of Oncology</i> , 2017, 28, 16-33.	1.2	865
5	OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. <i>Annals of Oncology</i> , 2019, 30, 558-566.	1.2	493
6	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). <i>Annals of Oncology</i> , 2014, 25, 1871-1888.	1.2	402
7	International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?. <i>Journal of the National Cancer Institute</i> , 2010, 102, 456-463.	6.3	325
8	1st International consensus guidelines for advanced breast cancer (ABC 1). <i>Breast</i> , 2012, 21, 242-252.	2.2	291
9	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). <i>Breast</i> , 2014, 23, 489-502.	2.2	269
10	Phyllodes Tumor of the Breast. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 492-500.	0.8	205
11	ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). <i>Breast</i> , 2017, 35, 203-217.	2.2	203
12	International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1174-1181.	6.3	202
13	Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic. <i>Breast</i> , 2020, 52, 8-16.	2.2	188
14	Cardiovascular effects of systemic cancer treatment. <i>Cancer Treatment Reviews</i> , 2011, 37, 300-311.	7.7	183
15	Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. <i>Annals of Oncology</i> , 2008, 19, 1090-1096.	1.2	168
16	European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. <i>Lancet Oncology</i> , The, 2022, 23, e21-e31.	10.7	117
17	Management of locally advanced breast cancer—perspectives and future directions. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 147-162.	27.6	113
18	ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. <i>ESMO Open</i> , 2020, 5, e000793.	4.5	113

#	ARTICLE	IF	CITATIONS
19	The requirements of a specialist breast centre. <i>Breast</i> , 2020, 51, 65-84.	2.2	111
20	Outcome and prognostic factors in breast sarcoma: A multicenter study from the rare cancer network. <i>Radiotherapy and Oncology</i> , 2007, 85, 355-361.	0.6	107
21	Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives. <i>Cancer Treatment Reviews</i> , 2017, 53, 98-110.	7.7	101
22	Cardiovascular effects of breast cancer radiotherapy. <i>Cancer Treatment Reviews</i> , 2007, 33, 578-593.	7.7	91
23	ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer. <i>Radiotherapy and Oncology</i> , 2019, 137, 159-166.	0.6	80
24	International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)â€”MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. <i>Breast</i> , 2013, 22, 203-210.	2.2	77
25	Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. <i>European Journal of Cancer</i> , 2019, 120, 20-30.	2.8	75
26	The effects of tamoxifen on the female genital tract. <i>Cancer Treatment Reviews</i> , 2004, 30, 291-301.	7.7	59
27	Time for more optimism in metastatic breast cancer?. <i>Cancer Treatment Reviews</i> , 2014, 40, 220-228.	7.7	59
28	Management of Adenoid Cystic Carcinoma of the Breast: A Rare Cancer Network Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 2118-2124.	0.8	58
29	Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3â€”98. <i>Psycho-Oncology</i> , 2014, 23, 173-182.	2.3	55
30	Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 904-910.	0.8	52
31	BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland. <i>Oncology Reports</i> , 2008, 19, 263-8.	2.6	51
32	Estrogen receptor-negative progesterone receptor-positive breast cancer â€” â€œNobody's landâ€” or just an artifact?. <i>Cancer Treatment Reviews</i> , 2018, 67, 78-87.	7.7	46
33	Vinflunineâ€”gemcitabine versus vinflunineâ€”carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1). <i>Annals of Oncology</i> , 2016, 27, 449-454.	1.2	45
34	Alveolar Rhabdomyosarcoma of the Uterine Cervix. <i>Gynecologic Oncology</i> , 1996, 63, 398-403.	1.4	30
35	Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 100, 102264.	7.7	29
36	Intraocular malignant teratoid medulloepithelioma in an adult: clinicopathological case report and review of the literature. <i>Acta Ophthalmologica</i> , 2006, 84, 259-262.	0.3	28

#	ARTICLE	IF	CITATIONS
37	OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline <i>BRCA</i> mutation (gBRCAm).. Journal of Clinical Oncology, 2017, 35, LBA4-LBA4.	1.6	28
38	OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline <i>BRCA1/2</i> mutations and high-risk HER2-negative early breast cancer.. Journal of Clinical Oncology, 2021, 39, LBA1-LBA1.	1.6	26
39	Over-treatment in metastatic breast cancer. Breast, 2017, 31, 309-317.	2.2	25
40	Epithelioid Sarcoma of the Bartholin's Gland Primarily Diagnosed as Vulvar Carcinoma. Gynecologic Oncology, 1994, 54, 393-395.	1.4	24
41	Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer. Annals of Oncology, 2017, 28, 2481-2488.	1.2	24
42	Radiotherapy for breast cancer in patients undergoing breast reconstruction or augmentation. Cancer Treatment Reviews, 2004, 30, 671-682.	7.7	21
43	Cardiac Involvement at Presentation of Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2008, 26, 1010-1011.	1.6	19
44	Changes in lateral dimensions of irradiated volume and their impact on the accuracy of dose delivery during radiotherapy for head and neck cancer. Radiotherapy and Oncology, 2006, 79, 304-309.	0.6	17
45	De-escalation of axillary irradiation for early breast cancer – Has the time come?. Cancer Treatment Reviews, 2021, 101, 102297.	7.7	16
46	Management Strategies for Hyperglycemia Associated with the \pm -Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer. Cancers, 2022, 14, 1598.	3.7	16
47	Patient-related factors determining geometry of intracavitary applicators and pelvic dose distribution during cervical cancer brachytherapy. International Journal of Radiation Oncology Biology Physics, 1997, 37, 531-536.	0.8	13
48	Olaparib versus chemotherapy treatment of physician's choice in patients with a germline <i>BRCA</i> mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases.. Journal of Clinical Oncology, 2018, 36, 1052-1052.	1.6	10
49	Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype. International Journal of Clinical and Experimental Pathology, 2014, 7, 353-63.	0.5	9
50	Mobile applications for early breast cancer chemotherapy-related symptoms reporting and management: A scoping review. Cancer Treatment Reviews, 2022, 105, 102364.	7.7	8
51	microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers Is Mainly Dependent on HER2 Status – A Pilot Study. Diagnostics, 2020, 10, 617.	2.6	7
52	Lost but Not Least – Novel Insights into Progesterone Receptor Loss in Estrogen Receptor-Positive Breast Cancer. Cancers, 2021, 13, 4755.	3.7	7
53	First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial.. Journal of Clinical Oncology, 2015, 33, 4503-4503.	1.6	5
54	Synchronous and metachronous metastatic breast cancer – Two incarnations of the same beast?. Breast, 2014, 23, 1.	2.2	4

#	ARTICLE	IF	CITATIONS
55	OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).. Journal of Clinical Oncology, 2017, 35, LBA4-LBA4.	1.6	4
56	High expression of progesterone receptor may be an adverse prognostic factor in oestrogen receptor-negative/progesterone receptor-positive breast cancer: results of comprehensive re-evaluation of multi-institutional case series. Pathology, 2022, 54, 269-278.	0.6	4
57	Second lower genital tract squamous cell carcinoma following cervical cancer. Acta Obstetrica Et Gynecologica Scandinavica, 2000, 79, 765-770.	2.8	3
58	Are bilateral breast cancers and breast cancers coexisting with ovarian cancer different from solitary tumors? A pair-matched immunohistochemical analysis aimed at intrinsic tumor phenotype. Pathology International, 2014, 64, 508-517.	1.3	3
59	A call back to reality!. Nature Reviews Clinical Oncology, 2015, 12, 67-68.	27.6	3
60	EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician's choice (TPC) in OlympiAD.. Journal of Clinical Oncology, 2018, 36, 1045-1045.	1.6	3
61	Exacerbation of diabetes related to exemestane treatment. Acta Oncologica, 2008, 47, 1167-1169.	1.8	2
62	Breast cancer units "Improvement in care or expensive "wishful thinking". Breast, 2014, 23, 199-200.	2.2	2
63	Comparison of claudin-3 and claudin-4 expression in bilateral and unilateral breast cancer. Neoplasma, 2021, 68, 283-289.	1.6	2
64	Feasibility and activity of two vinflunine (VFL)-based combinations as first-line chemotherapy (CT) in CDDP-unfit patients (pts) with advanced urothelial carcinoma (UC): VFL-gemcitabine (GEM) or VFL-CBDCA in a randomized international phase II trial (JASINT).. Journal of Clinical Oncology, 2014, 32, 4534-4534.	1.6	2
65	ER-/PgR+ breast cancer is a separate entity characterized by distinct phenotype: Comprehensive reevaluation of cases from Polish and Hungarian centers.. Journal of Clinical Oncology, 2020, 38, e12554-e12554.	1.6	2
66	EPIK-B5: A phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) progressing on/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i).. Journal of Clinical Oncology, 2022, 40, TPS1109-TPS1109.	1.6	2
67	Sunitinib in breast cancer: Friend or foe. Breast, 2009, 18, 211-212.	2.2	1
68	Are bilateral breast cancers different from breast cancers coexisting with ovarian cancer? An immunohistochemical analysis aimed at intrinsic tumor phenotype. Breast, 2013, 22, 425-430.	2.2	1
69	Metastatic Breast Cancer: Prognosis, Diagnosis and Oncological Management. , 2018, , 579-594.		1
70	Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis focused on cell cycle regulation. Histology and Histopathology, 2018, 33, 55-64.	0.7	1
71	Response: Re: International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy. Journal of the National Cancer Institute, 2010, 102, 207-208.	6.3	0
72	The need for post-mastectomy radiotherapy in patients with IBC. Nature Reviews Clinical Oncology, 2015, 12, 370-370.	27.6	0

#	ARTICLE	IF	CITATIONS
73	Breast Cancer in Young Women - News from the BCY3 Consensus Conference. Breast Care, 2016, 11, 432-435.	1.4	0
74	New horizon in breast cancer therapy: highlights from the European Society for Medical Oncology. ESMO Open, 2017, 2, e000204.	4.5	0
75	Locally Advanced Breast Cancer. , 2018, , 567-578.		0
76	Czy wydÅ, uÅ¼ona pooperacyjna hormonoterapia powinna byÄ± standardowym postÄ™powaniem u chorych na raka piersi? GÅ, os na TAK. Nowotwory, 2015, 65, 59-61.	0.3	0
77	miRNA signatures of prognostic significance in single hormone receptor-positive breast cancer.. Journal of Clinical Oncology, 2022, 40, e12544-e12544.	1.6	0